Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × FP-1039 × Clear all

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Neoplasms 1

Interventions

Cisplatin 1347 Carboplatin 1263 Cyclophosphamide 1203 Bevacizumab 1100 Gemcitabine 1094 Paclitaxel 1082 Radiotherapy 1061 Docetaxel 982 pembrolizumab 910 Oxaliplatin 831 Capecitabine 810 Fluorouracil 760 Rituximab 662 Doxorubicin 604 Nivolumab 596 Dexamethasone 594 Etoposide 587 Irinotecan 565 Leucovorin 522 Pemetrexed 449 Drug Therapy 426 Cetuximab 421 Trastuzumab 414 Cytarabine 411 Magnetic Resonance Spectroscopy 399 Filgrastim 394 Prednisone 387 Lenalidomide 358 Bortezomib 357 Temozolomide 352

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01244438 2021-12-13

Study of FP-1039 in Subjects With Endometrial Cancers

Five Prime Therapeutics, Inc.

Phase 2 Withdrawn

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡